All In Biotech

Drug Trial Radar · NCT01838395

Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

A Phase IIa, Multicenter, Open-Label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

42

Actual

Start

Apr 2013

Primary completion

Mar 2016

Study completion Jul 20, 2023

Sponsor

Lead sponsor
BioLineRx, Ltd.Industry
Sponsor type
Industry
First posted
Apr 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study is designed to assess if BL-8040 in combination with cytarabine (Ara-C) can help controlling the disease in patients with Acute Myeloid Leukemia (AML) that have relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Ara-CDrug

    IV (intravenous administration)

  • BL-8040Drug

    SC (subcutaneous injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Participants were followed for the duration of the hospital stay and the follow-up period, an expected average of 6 weeks.

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • MD Anderson Cancer Center

    Houston, Texas

  • Rambam Medical Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Meir Medical Center

    Kfar Saba, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.